The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Aurinia Pharmaceuticals Inc shares valued at $10,120,000 were purchased by TANG KEVIN on Aug 01 ’25. At $10.12 per share, TANG KEVIN acquired 1,000,000 shares. The insider’s holdings grew to 11,029,500 shares worth approximately $128.05 million following the completion of this transaction.
Also, TANG KEVIN purchased 200,000 shares, netting a total of over 2,336,000 in proceeds. Following the buying of shares at $11.68 each, the insider now holds 11,329,500 shares.
Before that, TANG KEVIN had added 100,000 shares to its account. In a trade valued at $1,134,000, the Director bought Aurinia Pharmaceuticals Inc shares for $11.34 each. Upon closing the transaction, the insider’s holdings increased to 100,000 shares, worth approximately $129.21 million.
Analysts at Oppenheimer downgraded the stock from ‘”an Outperform”‘ to ‘”a Perform”‘ outlook in a report released in early November. Earlier on December 10, 2021, Oppenheimer upgraded its rating. Their new recommendation was “an Outperform” for AUPH stock which previously was a “a Perform”.
Analyzing AUPH Stock Performance
On last trading session, Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] plunged -0.77% to $11.61. The stock’s lowest price that day was $11.355, but it reached a high of $11.79 in the same session. During the last five days, there has been a surge of approximately 28.29%. Over the course of the year, Aurinia Pharmaceuticals Inc shares have jumped approximately 111.09%.
Is Aurinia Pharmaceuticals Inc subject to short interest?
Stocks of Aurinia Pharmaceuticals Inc saw a sharp rise in short interest on 2025-07-15 jumping by 96414.0 shares to 10.63 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 10.53 million shares. A jump of 0.91% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.1 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.1.
Which companies own the most shares of Aurinia Pharmaceuticals Inc (AUPH)?
In terms of Aurinia Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 12 in the next 12 months, up nearly 2.56% from the previous closing price of $11.7. Analysts anticipate Aurinia Pharmaceuticals Inc stock to reach 13 by 2025, with the lowest price target being 6. In spite of this, 3 analysts ranked Aurinia Pharmaceuticals Inc stock as Buy at the end of 2025. On October 28, 2021, Oppenheimer assigned a price target of “a Perform” to the stock and downgraded coverage with a $32.
